CHU de Clermont-Ferrand, Service de Cytogénétique Médicale, Hôpital Estaing, Clermont-Ferrand, France.
U1240 Imagerie Moléculaire et Stratégies Théranostiques, INSERM, Université Clermont Auvergne, Clermont Ferrand, France.
Pediatr Blood Cancer. 2018 Dec;65(12):e27404. doi: 10.1002/pbc.27404. Epub 2018 Sep 14.
In high-risk neuroblastoma (HR-NB), the clinical significance of long-term minimal residual disease (MRD) monitoring using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) for neuroblastoma mRNAs has not been investigated. We report long-term MRD follow-ups of four patients with HR-NB throughout the disease (diagnosis, remission, and relapse) and treatment course (chemotherapy, autologous and allogeneic stem cell transplantation, and donor lymphocyte and natural killer cell infusions). The results showed the stability of mRNA marker expression after different treatments and demonstrated their validity to predict relapse and assess therapeutic response. This opens up the possibility of investigating the utility of long-term molecular monitoring of MRD in prospective multicenter studies.
在高危神经母细胞瘤（HR-NB）中，使用定量逆转录聚合酶链反应（qRT-PCR）检测神经母细胞瘤 mRNA 的长期微小残留病（MRD）监测的临床意义尚未得到研究。我们报告了 4 例 HR-NB 患者在疾病（诊断、缓解和复发）和治疗过程（化疗、自体和异基因干细胞移植以及供体淋巴细胞和自然杀伤细胞输注）中的长期 MRD 随访结果。结果表明，不同治疗后 mRNA 标志物表达的稳定性，并证明其可用于预测复发和评估治疗反应。这为在前瞻性多中心研究中探讨长期分子监测 MRD 的实用性提供了可能。
